lifestyle.careersavvy.co.uk

Author: Orion Oyj

Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA

April 20, 2026
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines

April 1, 2026